LSEG Group Strategy and Performance - LSEG's diversified business model delivers strong financial performance, with 73% high-quality recurring revenues and structurally growing transactional revenues[26, 27] - LSEG has a track record of uncorrelated, all-weather growth, delivering Earnings per Share (EPS) CAGR of 15% and Dividend per Share (DPS) CAGR of 18% over the last 20 years[32, 34] - Free cash flow continues to trend upward, expected to hit £2.4 billion in 2025[36] - LSEG has delivered £292 million revenue and £562 million cost synergies[48] Data & Analytics Strategy and Monetization - Data & Analytics represents 47% of LSEG's £3.9 billion income in 2024[13] - LDAs are forecast to account for 17% of D&A ASV by the end of 2025[68] - Tick History is experiencing 39% p a growth in use[155] - Since 2021, D&A revenue growth has been accelerating, with >5 0% organic constant currency growth expected in FY2025[161] AI Strategy and Engineering Transformation - LSEG is the global 1 in real-time data[107] - LSEG's engineering transformation strategy focuses on Exceptional Talent, Common Platforms, and Product Discipline to accelerate product development and AI adoption[92, 93] - LSEG is transforming data onboarding and customer operations with AI, achieving results such as 9x faster content extraction and a 51% FTE reduction in the central sourcing team[127, 128] New Products and Services - ForexClear clears only 1% of the FX market, driven by FX Options and NDFs, which are subject to the Uncleared Margin Rules (UMR), generating over £50 million in annual revenue[380] - The Private Securities Market (PSM) charges companies an admission fee of £25,000 a year for access to 2 auctions, buyers will pay 0 75% on value of shares bought, sellers will pay 1% on value of shares sold[360, 361]

(NASDAQ: VIOT) Company Presentation Safe Harbor Statement This presentation has been prepared by Viomi Technology Co., Ltd ("Viomi" or the "Company") solely for informational purposes and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. This docu ...

Financial Performance - LINZESS U S net sales reached $315 million in Q3 2025, a 40% year-over-year increase, driven by improved net pricing and a 12% year-over-year growth in EUTRx demand[11] - Ironwood generated $40 million in GAAP net income and $82 million in adjusted EBITDA in Q3 2025[11] - The company's share of net profit from the LINZESS U S brand collaboration was $119 515 million for the three months ended September 30, 2025[15] - Ironwood's collaborative arrangements revenue was $119 646 million for the three months ended September 30, 2025[15] - Ironwood ended Q3 2025 with $140 million in cash and cash equivalents[11] Guidance and Expectations - Full-year LINZESS U S net sales guidance was raised to $860 - $890 million, and total revenue guidance to $290 - $310 million[11] - Adjusted EBITDA guidance was raised to greater than $135 million[11] LINZESS Performance - LINZESS extended unit (EUTRx) and new to brand (NBRx) prescriptions each grew 12% year-over-year in Q3 2025[12] - LINZESS U S net product sales as reported by AbbVie were $314 856 million for the three months ended September 30, 2025[15] Strategic Developments - In November 2025, the FDA approved LINZESS as the first drug for the treatment of children 7 years and older with irritable bowel syndrome with constipation (IBS-C)[11] - The company plans to align with the FDA in Q4 2025 on confirmatory Phase 3 trial design for Apraglutide, with trial initiation expected in 1H 2026[7]

Financial Performance - VEON delivered strong revenue growth of 7.5% in USD and 11% in local currency (LCY), outpacing inflation at 8.4%[11] - EBITDA grew by 19.7% in USD and 24.2% in LCY[11, 20] - Direct digital revenues increased significantly by 63.1% in USD, representing 17.8% of total revenues[11] - LTM equity free cash flow (FCF) reached $584 million, demonstrating sustained FCF momentum[12, 13] - Earnings per ADS increased by 73.6% to $7.81 for 9M25 and by 60.2% to $8.89 for LTM[13] Digital Growth and Strategy - Digital engagement is accelerating, surpassing mobile engagement in monthly usage[12] - VEON is integrating AI-powered features into its digital applications[12] - The company is committed to the combined power of DO1440 and AI1440[12] - Total digital monthly active users (MAU) reached 143.3 million, a 39.3% year-over-year increase[28] Strategic Initiatives - VEON completed the sale of its Kyrgyzstan business[12] - The company is advancing infrastructure monetization across all markets[12] - VEON pioneered Direct to Cell satellite connectivity in its markets[12] - A new buyback plan of up to $100 million of ADS and/or bonds was announced[12] Regional Performance - Pakistan's total revenue increased by 14.6% in LCY, with direct digital revenue up by 28.5%[24] - Ukraine's total revenue grew by 21.1% in LCY, with direct digital revenue increasing 5.3x[24] - Kazakhstan's total revenue increased by 6.7% in LCY, with direct digital revenue up by 43.1%[24] - Uzbekistan's total revenue increased by 9.3% in LCY, with direct digital revenue increasing 2.4x[24]

Financial Performance Highlights - FY2025 net sales reached $1,430 million, with a 5-year CAGR of 8.2%[12] - Adjusted EBITDA for FY2025 was $326.2 million, representing 22.8% of net sales and a 5-year CAGR of 11.3%[12] - Free cash flow for FY2025 amounted to $172 million[12] - Net debt stood at $20.1 million as of September 30, 2025, with a net debt to adjusted EBITDA ratio of 0.1x[12] - Q4 Fiscal 2025 net sales were $380.8 million, a 9.4% increase year-over-year[71] - Q4 Fiscal 2025 adjusted EBITDA was $91.8 million, a 26.6% increase year-over-year[71] - Q4 Fiscal 2025 adjusted net income per diluted share was $0.38, a 72.7% increase year-over-year[71] Strategic Priorities and Investments - The company aims to identify a total of 18 billion gallons of water loss by 2029 through EchoShore® leak detection[20] - Capital expenditures are expected to increase to 4% to 5% of net sales over the next 3 years[77] - The company has allocated $95 million to share repurchases since FY2019, including $15 million in FY2025, with $65 million remaining authorization on the share repurchase program as of September 30, 2025[93] FY2026 Outlook - Consolidated net sales are projected to be between $1,450 million and $1,470 million, representing a year-over-year growth of 1.4% to 2.8%[87] - Adjusted EBITDA is expected to range from $345 million to $350 million, indicating a year-over-year growth of 5.8% to 7.3%[87]

Investor Presentation (NASDAQ: CBAT) Technology, Inc. November 2025 CBAK Energy ©2025 CBAK. All Rights Reserved. The First Chinese Li-ion Battery Manufacturer Listed in NASDAQ Disclaimer Powering a Sustainable Life with Electricity Disclaimers and Other Important Information This presentation (the "Presentation") about CBAK Energy Technology, Inc. (the "Company" or "CBAK") is dated as of March 2021. It is information in a summary form and does not purport to be complete. The data contained herein is derived ...

Company Overview - Standard Lithium aims to be a leading low-cost, sustainable U S lithium producer [22] - The company plans for near-term commercial-scale production using innovative technologies on its Arkansas and Texas assets [24] - The company is developing projects with global partners, benefiting from stakeholder and regulatory support [26] Resource and Project Highlights - The Smackover Formation is a premier lithium resource in North America, with concentrations up to 616 mg/L in Arkansas and 806 mg/L in East Texas [27] - The South West Arkansas (SWA) Project has been awarded a $225 million grant from the U S Department of Energy (DOE) [27] - The SWA Project is targeting commercial production in 2028, with an initial capacity of 22,500 tonnes per annum (TPA) of lithium carbonate [30, 38] - The East Texas Projects have the potential for over 100,000 TPA LCE production across three projects [38] Market and Economics - Global lithium demand is projected to reach 2.8 million tonnes of lithium carbonate equivalent (LCE) by 2030 [27] - The SWA Project DFS indicates a $1.7 billion unlevered pre-tax NPV and a 20% pre-tax IRR, with a total CAPEX of $1.449 billion [40]

American Heart Association 2025 Investor Presentation November 9, 2025 Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This presentation of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. ...

Kidney Program Updates at the American Society of Nephrology Kidney Week 2025 November 8, 2025 ©2025 Vertex Pharmaceuticals Incorporated ©2025 Vertex Pharmaceuticals Incorporated Presentation intended for the investment community Agenda Welcome Susie Lisa, CFA, Senior Vice President, Investor Relations, Vertex Pharmaceuticals Kidney portfolio Reshma Kewalramani, M.D., President and Chief Executive Officer, Vertex Pharmaceuticals RUBY-3 late breaking data recap James A. Tumlin, M.D., Professor of Medicine in ...

Financial Performance - Viasat reported Q2 FY2026 revenue of $1.141 billion, a 2% increase compared to $1.122 billion in Q2 FY2025[20, 23] - Adjusted EBITDA for Q2 FY2026 was $385 million, a 3% increase compared to $375 million in Q2 FY2025[21, 23] - The company generated $69 million in free cash flow during the quarter, a $58 million improvement year-over-year[22] - For the twelve months ended September 30, 2025, Viasat generated $147 million in free cash flow[22] - Operating cash flow increased by 18% YoY, from $239 million to $282 million[23] Segment Performance - Communication Services (CS) revenue grew 1% YoY, reaching $837 million in Q2 FY26[23, 27] - Defense and Advanced Technologies (DAT) segment revenues grew 3% YoY, reaching $304 million in Q2 FY26[23, 39] - CS segment Adjusted EBITDA increased 6% YoY to $337 million[23, 29] - DAT segment Adjusted EBITDA declined 15% YoY to $48 million[23, 41] Awards and Backlog - Total awards increased 17% YoY to $1.498 billion[19, 23] - CS segment awards increased 35% YoY to $1.031 billion[23, 26] - DAT awards declined 9% YoY to $467 million[23, 37] - DAT segment backlog grew 31% to a record $1.2 billion[23, 36, 45]